Health TrialsbyHealthPanel

Light-Chain Amyloidosis

4

Review clinical trials related to Light-Chain Amyloidosis. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Not yet recruiting

Phase 1a/b Study of GPRC5D CART Therapy in Relapsed/Refractory Multiple Myeloma and Light-chain Amyloidosis

A Phase 1a/b Open-Label Study to Evaluate Safety and Preliminary Efficacy of GPRC5D CART Therapy for the Treatment of Relapsed/Refractory Multiple Myeloma and Light-chain Amyloidosis.

Participants needed: 160
Trial details
Phase: Phase 1Age: 18+Biological sex: AllType: InterventionalSponsor: Hadassah Medical OrganizationUpdated: Oct 14, 2026Locations: 1
Eligibility criteria

≥18 years of age at the time of signing informed consent. [+19]

Known bulky central nervous system disease. [+19]

Read more
Status: Recruiting

A Phase 1b/2 Study of CAR T Cell Therapy Targeting CD19 and BCMA in Participants With Relapsed or Refractory AL Amyloidosis.

Open-label Phase 1b/2 study with primary objective of this study is to evaluate the safety, tolerability and efficacy of AZD0120 in participants with light chain (AL) amyloidosis.

Participants needed: 91
Trial details
Phase: Phase 1, Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: Alexion Pharmaceuticals, Inc.Updated: Jul 2, 2026Locations: 18
Eligibility criteria

Confirmed histopathological diagnosis of AL amyloidosis [+6]

Have any other form of amyloidosis other than AL amyloidosis [+11]

Read more
Status: Recruiting

Study of HBI0101 (NXC-201) CAR-T Therapy in Multiple Myeloma and Light-Chain Amyloidosis

A Phase II study of HBI0101 (NXC-201) BCMA-CART in Multiple Myeloma and Light-chain Amyloidosis Patients. The goal of the study is to evaluate the efficacy and safety of HBI0101 CART.

Participants needed: 180
Trial details
Phase: Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: Polina StepenskyUpdated: May 14, 2025Locations: 1
Eligibility criteria

≥18 years of age at the time of signing informed consent. [+8]

Contraindication to a study treatment/procedure or is anticipated to receive tre... [+19]

Read more
Status: Recruiting

FKC288 for Relapsed or Refractory Systemic Light Chain (AL) Amyloidosis

This study is a single-center exploratory clinical trial. It is estimated that 6-12 subjects will be enrolled. The "BOIN" dose escalation design is adopted. The main purpose is to evaluate the safety of FKC288 in the treatment of subjects with relapsed or refractory AL amyloidosis and explore the recommended phase II dose of FKC288 in the treatment of patients with relapsed/refractory systemic Light Chain (AL) amyloidosis.

Participants needed: 12
Trial details
Phase: Phase 1Age: 18-70Biological sex: AllType: InterventionalSponsor: Nanjing University School of MedicineUpdated: Nov 15, 2023Locations: 1
Eligibility criteria

The subject must personally sign a written informed consent form approved by the... [+7]

Subjects who have received any of the following treatments prior to enrollment:... [+16]

Read more